• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2021.16063

Clinical and laboratory markers for different variants of the course of irritable bowel syndrome

[Original research] [Internal diseases]
Tatyana Tikhonova; Irina Kozlova; Igor Kvetnoy; Eduard Fedotov; Yulia Sergeevna Krylova;

The aim of the study was to identify markers of various variants of the course of irritable bowel syndrome (IBS). In 148 patients with a confirmed diagnosis of IBS, fibrocolonoscopy, biopsy, general morphological, immunohistochemical, and morphometric studies of colobioptats were performed to determine the expression area and optical density of colonocytes immunopositive to motilin and sirtuin-1, and the genotypes of polymorphic markers rs5743836 and rs352140 of the TLR9 gene were determined by polymerase chain reaction. In the refractory variant of IBS, chronic nonspecific mucosal inflammation was detected in combination with signs of focal atrophy of the colon mucosa. Changes in the area of expression and optical density of motilin- and sirtuin-1-positive colonocytes were found, the most significant changes were in the refractory variant of the disease. Different variants of the course of IBS were associated with different frequencies of genotypes of polymorphic markers rs352140, rs5743836 of the TLR9 gene. In refractory IBS, homozygous genotypes of polymorphic markers were more common.

Download

References:
1. Holtmann G., Shah A., Morrison M. Pathophysiology of functional gastrointestinal disorders: a holistic overview. Dig. Dis. 2017;35(l):5-13.
https://doi.org/10.1159/000485409
2. Holtmann G. J., Ford A. C., Talley N. J. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol. Hepatol. 2016;1:133-146.
https://doi.org/10.1016/S2468-1253(16)30023-1
3. Bellono N. W., Bayrer J. R., Leitch D. B., Castro J., Zhang C. [et al.]. Enterochromaffin cells are gut chemosensors that couple to sensory neural pathways. Cell. 2017;170(1):185- 198.e16.
https://doi.org/10.1016/j.cell.2017.05.034
4. Hardeland R. Melatonin and inflammation-Story of a double-edged blade. J. Pineal.Res. 2018;65(4):e12525.
https://doi.org/10.1111/jpi.12525
5. Yao X., Chen W., Liu J., Liu H., Zhan J. Y. [et al.]. Deep vein thrombosis is modulated by inflammation regulated via Sirtuin 1/NF-κB signalling pathway in a rat model. Thromb. Haemost. 2019;119(3):421-430.
https://doi.org/10.1055/s-0038-1676987
6. Hwang J. W., Yao H., Caito S., Sundar I. K., Rahman I. Redox regulation of SIRT1 in inflammation and cellular senescence. Free Radic. Biol. Med. 2013;61:95-110.
https://doi.org/10.1016/j.freeradbiomed.2013.03.015272
7. Takeda K., Akira S. Toll-like receptors. Curr. Protoc. Immunol. 2015;109:14.12.1-14.12.10.
https://doi.org/10.1002/0471142735.im1412s109
8. Mukherjee S., Huda S., Sinha Babu S. P. Toll-like receptor polymorphism in host immune response to infectious diseases: a review. Scand. J. Immunol. 2019;90(1):e12771.
https://doi.org/10.1111/sji.12771
9. de la Fuente S., Citores M. J., Lucena J. L., Muñoz P., Cuervas-Mons V. TLR9-1486C/T polymorphism is associated with hepatocellular carcinoma recurrence after liver transplantation. Biomark. Med. 2019;13(12):995-1004.
https://doi.org/10.2217/bmm-2019-0030
10. Liu C., Han C., Liu J. The role of Toll-like receptors in oncotherapy. Oncol. Res. 2019;27(8):965-978.
https://doi.org/10.3727/096504019X15498329881440
11. Kordjazy N., Haj-Mirzaian A., Rohani M. M., Gelfand E. W., Rezaei N. [et al.]. Role of toll-like receptors in inflammatory bowel disease. Pharmacol. Res. 2018;129:204-215.
https://doi.org/10.1016/j.phrs.2017.11.017
12. Ivashkin V. T., Shelygin Yu. A., Baranskaya Ye. K., Belousova Ye. A., Beniashvili A. G. [et al.]. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Rossijskij zhurnal gastrojenterologii, gepatologii i koloproktologii. – Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(5):76-93. (In Russ.).
https://doi.org/10.22416/1382-4376-2017-27-5-76-93
13. Morisky D. E., Green L. W., Levine D. M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med. Care. 1986;24(1):67-74.
https://doi.org/10.1097/00005650-198601000-00007
14. Masuy I., Pannemans J., Tack J. Irritable bowel syndrome: diagnosis and management. Minerva Gastroenterol. Dietol. 2020;66(2):136-150.
https://doi.org/10.23736/S1121-421X.19.02640-0
15. Lackner J. M., Jaccard J., Keefer L., Brenner D. M., Firth R. S. [et al.]. Improvement in gastrointestinal symptoms after cognitive behavior therapy for refractory irritable bowel syndrome. Gastroenterology. 2018;155(1):47-57.
https://doi.org/10.1053/j.gastro.2018.03.063
16. Xue H., Peng H., Li J., Li M., Lu S. TLR9 rs352140 polymorphism contributes to a decreased risk of bacterial meningitis: evidence from a meta-analysis. Epidemiol. Infect. 2020;148:e294.
https://doi.org/10.1017/S0950268820002666
17. Ng Q. X., Soh A. Y. S., Loke W., Lim D. Y., Yeo W. S. The role of inflammation in irritable bowel syndrome (IBS). J. Inflamm. Res. 2018;11:345-349.
https://doi.org/10.2147/JIR.S174982
18. Deloose E., Verbeure W., Depoortere I., Tack J. Motilin: from gastric motility stimulation to hunger signalling. Nat. Rev. Endocrinol. 2019;15(4):238-250.
https://doi.org/10.1038/s41574-019-0155-0
19. Sanger G. J., Broad J., Callaghan B., Furness J. B. Ghrelin and motilin control systems in gi physiology and therapeutics. Handb. Exp. Pharmacol. 2017;239:379-416.
https://doi.org/10.1007/164_2016_104
20. Kozlova I. V., Tikhonova T. A., Krylova Yu. S. Refractory irritable bowel syndrome in adults: psychological characteristics, morphometric aspects of the diffuse endocrine system. Terapija. – Therapy. 2019;3(29):26-31. (In Russ.).
https://doi.org/10.18565/therapy.2019.3.26-31
21. Tikhonova T. A., Kozlova I. V., Fedotov E. A. Genetic and psychological prerequisites for development of refractory variant of irritable bowel syndrome. Jeksperimental’naja i klinicheskaja gastrojenterologija. – Experimental and Clinical Gastroenterology. 2019;2:68-74. (In Russ.).
https://doi.org/10.31146/1682-8658-ecg-162-2-68-74
22. Vijay K. Toll-like receptors in immunity and inflammatory diseases: past, present, and future. Int. Immunopharmacol. 2018;59:391-412.
https://doi.org/10.1016/j.intimp.2018.03.002

Keywords: irritable bowel syndrome, refractoriness to treatment, colonocytes, immunopositivity to motilin, sirtuin-1, Toll-like receptor genes polymorphism